Weiss & Lurie, a national class action and shareholder rights law firm with offices in New York City and Los Angeles, is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Synovis Life Technologies, Inc. (“Synovis” or the “Company”) (Nasdaq: SYNO) arising from its agreement to be acquired by Baxter International, Inc. Under the merger agreement, Synovis shareholders will receive $28.00 cash for each Synovis share. The proposed transaction has a total value of $325 million.
Weiss & Lurie is investigating whether Synovis’ Board acted in the best interests of shareholders in approving the transaction, including whether the consideration being paid to shareholders is fair in light of the true inherent value of the Company, and whether the Board engaged in an adequate sales process. If you own Synovis shares and would like more information about your rights as a shareholder or additional information concerning our investigation, please contact Richard A. Acocelli either by email at
or by telephone at (888) 593-4771.
Weiss & Lurie has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties. We have recovered over a billion dollars for defrauded institutions and individuals and obtained important corporate governance in these cases. If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or issuing materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at
or fill out the form on our website,
Attorney Advertising. Past results do not guarantee a similar outcome.